Product Name | NebuSelect™ Recombinant Human PCSK9, His-tag |
---|---|
Catalog Number | NBL-240838 |
Alias/Synonyms | PCSK9; PC9; PCSK9; FH3; HCHOLA3; LDLCQ1; NARC-1 |
Appearance | see COA |
Molecule Weight | Gln31-Gln692 |
CAS | N/A |
Solubility | Water Soluble |
Storage | Short term 4℃; Long term -20℃. |
Shelf Life | 2 years |
Additional info 1 | Q8NBP7-1 |
Additional info 2 |
Catalog Numbe | Size | Price | Inventory Level | |
NBL-240838-100ug | 100ug | Inquire | Inquire | |
NBL-240838-1mg | 1mg | Inquire | Inquire | |
NBL-240838-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human PCSK9, His-tag
Catalog#:
NBL-240838
Description:
NebuSelect™ Recombinant Human PCSK9, His-tag(Cat#NBL-240838) is expressed in HEK293 with His tag at the C-Terminus.It contains Gln31-Gln692.
Species:
Human
Expression System:
HEK293
Molecular Weight:
Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-68 kDa (pro-form) and 15kDa (mature form) based on Bis-Tris PAGE result.
Target Name:
PCSK9; PC9; PCSK9; FH3; HCHOLA3; LDLCQ1; NARC-1
Target Information:
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
Amino Acid Sequence:
Gln31-Gln692
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.